NasdaqGM - Delayed Quote USD

ANI Pharmaceuticals, Inc. (ANIP)

65.36 +0.41 (+0.63%)
At close: April 26 at 4:00 PM EDT
67.31 +1.95 (+2.98%)
After hours: April 26 at 7:29 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
486,816.00
486,816.00
316,385.00
216,136.00
208,475.00
Cost of Revenue
181,513.00
181,513.00
138,785.00
100,610.00
87,157.00
Gross Profit
305,303.00
305,303.00
177,600.00
115,526.00
121,318.00
Operating Expense
255,774.00
255,774.00
203,334.00
143,695.00
136,888.00
Operating Income
49,529.00
49,529.00
-25,734.00
-28,169.00
-15,570.00
Net Non Operating Interest Income Expense
-26,940.00
-26,940.00
-28,052.00
-11,922.00
-9,452.00
Other Income Expense
-2,717.00
-2,717.00
-8,879.00
-15,967.00
-940.00
Pretax Income
19,872.00
19,872.00
-62,665.00
-56,058.00
-25,962.00
Tax Provision
1,093.00
1,093.00
-14,769.00
-13,455.00
-3,414.00
Net Income Common Stockholders
17,154.00
17,154.00
-49,521.00
-42,793.00
-22,548.00
Diluted NI Available to Com Stockholders
17,154.00
17,154.00
-49,521.00
-42,793.00
-22,548.00
Basic EPS
0.86
0.86
-3.05
-3.40
-1.88
Diluted EPS
0.85
0.85
-3.05
-3.40
-1.88
Basic Average Shares
18,001.00
18,001.00
16,260.00
12,596.00
11,964.00
Diluted Average Shares
18,194.00
18,194.00
16,260.00
12,596.00
11,964.00
Total Operating Income as Reported
46,971.00
46,971.00
-35,283.00
-39,793.00
-16,016.00
Total Expenses
437,287.00
437,287.00
342,119.00
244,305.00
224,045.00
Net Income from Continuing & Discontinued Operation
18,779.00
18,779.00
-47,896.00
-42,603.00
-22,548.00
Normalized Income
21,196.31
21,196.31
-40,600.56
-33,768.76
-22,160.43
Interest Expense
26,940.00
26,940.00
28,052.00
11,922.00
9,452.00
Net Interest Income
-26,940.00
-26,940.00
-28,052.00
-11,922.00
-9,452.00
EBIT
46,812.00
46,812.00
-34,613.00
-44,136.00
-16,510.00
EBITDA
106,603.00
106,603.00
25,040.00
3,116.00
28,128.00
Reconciled Cost of Revenue
181,513.00
181,513.00
136,104.00
100,610.00
87,157.00
Reconciled Depreciation
59,791.00
59,791.00
59,653.00
47,252.00
44,638.00
Net Income from Continuing Operation Net Minority Interest
18,779.00
18,779.00
-47,896.00
-42,603.00
-22,548.00
Total Unusual Items Excluding Goodwill
-2,558.00
-2,558.00
-9,549.00
-11,624.00
-446.00
Total Unusual Items
-2,558.00
-2,558.00
-9,549.00
-11,624.00
-446.00
Normalized EBITDA
109,161.00
109,161.00
34,589.00
14,740.00
28,574.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-140.69
-140.69
-2,253.56
-2,789.76
-58.43
12/31/2020 - 5/5/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

COLL Collegium Pharmaceutical, Inc.
36.42
+1.62%
 
ETON Eton Pharmaceuticals, Inc.
3.4500
+10.58%
 
ALKS Alkermes plc
24.68
+0.98%
 
CRDL Cardiol Therapeutics Inc.
1.7900
-1.65%
 
EGRX Eagle Pharmaceuticals, Inc.
4.1600
-1.89%
 
PETQ PetIQ, Inc.
16.53
+1.29%
 
PAHC Phibro Animal Health Corporation
12.73
+2.33%
 
RDY Dr. Reddy's Laboratories Limited
74.55
+0.72%
 
SUPN Supernus Pharmaceuticals, Inc.
30.07
+2.59%
 
AVDL Avadel Pharmaceuticals plc
17.81
-0.06%